SCHEMBL21482082

SCHEMBL21482082

COC(=O)c1ccc(F)c2ccn(Cc3ccc(I)cc3)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
CHRM1 P11229 1/20 0.38
GAA P10253 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 5/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 2/20 0.35
MMP10 P09238 1/20 0.35
MMP13 P45452 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
ATM Q13315 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
PARP1 P09874 1/20 0.35
TP53 P04637 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601878 0.90 L3MBTL1 (0.46) KDM4ECHRM1GAAL3MBTL1MAPT
SCHEMBL21458237 0.89 HSP90AA1 (0.39) KDM4ECHRM1GAAL3MBTL1POLB
SCHEMBL30843268 0.89 HSP90AA1 (0.39) KDM4ECHRM1GAAL3MBTL1POLB
SCHEMBL21458142 0.87 CHRM1 (0.47) KDM4ECHRM1MAPTATMTP53
SCHEMBL30843266 0.87 CHRM1 (0.47) KDM4ECHRM1MAPTATMTP53
SCHEMBL21458220 0.86 EPHX2 (0.45) KDM4ECHRM1LMNA
SCHEMBL30843286 0.86 EPHX2 (0.45) KDM4ECHRM1LMNA
SCHEMBL30697457 0.85 CHRM1 (0.42) CHRM1NPSR1LMNASIGMAR1CNR1
SCHEMBL20541759 0.85 CHRM1 (0.42) CHRM1NPSR1LMNASIGMAR1CNR1
SCHEMBL26602446 0.84 MAPK10 (0.38) KDM4ECHRM1GAAL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KDM4E 719/4885CHRM1 594/4885GAA 4537/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 KDM4E 719/4885CHRM1 594/4885GAA 4537/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KDM4E 719/4885CHRM1 594/4885GAA 4537/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KDM4E 719/4885CHRM1 594/4885GAA 4537/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 KDM4E 719/4885CHRM1 594/4885GAA 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.